References
- ACCORD. 2010. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 362(17):1575–1585. 10.1056/NEJMoa1001286.
- Araújo J, Cai J, Stevens J. 2019. Prevalence of optimal metabolic health in American Adults: National Health and Nutrition Examination Survey 2009-2016. Metab Syndr Relat Disord. 17(1):46–52. doi: 10.1089/met.2018.0105.
- Blumberg J, Heaney RP, Huncharek M, Scholl T, Stampfer M, Vieth R, Weaver CM, Zeisel SH. 2010. Evidence-based criteria in the nutritional context. Nutr Rev. 68(8):478–484. doi: 10.1111/j.1753-4887.2010.00307.x.
- Bytyçi I, Bajraktari G, Bhatt DL, Morgan CJ, Ahmed A, Aronow WS, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. 2017. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. J Clin Lipidol. 11(3):624–637. doi: 10.1016/j.jacl.2017.03.003.
- Callaghan S, Losch M, Pione A, Teichner W. 2021. Feeling good: The future of the $1.5 trillion wellness market. https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/feeling-good-the-future-of-the-1-5-trillion-wellness-market.
- CCNR. 1949. A new dietary standard for Canada, 1949: Canadian council on nutrition Ottawa, Ontario. Can J Public Health Rev Can Santee Publique. 40(10):420–426. http://www.jstor.org/stable/41980247.
- Cena H, Calder PC. 2020. Defining a healthy diet: Evidence for the role of contemporary dietary patterns in health and disease. Nutrients. 12(2):334. https://www.mdpi.com/2072-6643/12/2/334. doi: 10.3390/nu12020334.
- Christensen JJ, Arnesen EK, Andersen R, Eneroth H, Erkkola M, Høyer A, Lemming EW, Meltzer HM, Halldórsson PI, Þórsdóttir I, Schwab U, Trolle E, Blomhoff R. 2020. The Nordic Nutrition Recommendations 2022 - principles and methodologies. Food Nutr Res. 64:1–10.
- Daniells S. 2023. FDA updates clinical trials guidance to align with ICH: What’s the impact for supplements? Nutraingredients. https://www.nutraingredients-usa.com/Article/2023/06/14/fda-updates-clinical-trials-guidance-to-align-with-ich-what-s-the-impact-for-supplements?utm.
- de Ridder D, Kroese F, Evers C, Adriaanse M, Gillebaart M. 2017. Healthy diet: Health impact, prevalence, correlates, and interventions. Psychol Health. 32(8):907–941. doi: 10.1080/08870446.2017.1316849.
- DuBroff R, de Lorgeril M. 2015. Cholesterol confusion and statin controversy. WJC. 7(7):404–409. doi: 10.4330/wjc.v7.i7.404.
- Fallon KC, Karlawish J. 2019. It’s time to change the definition of ‘health.’ STAT. https://www.statnews.com/2019/07/17/change-definition-health/.
- FDA. 2007. Guidance for industry: Developing products for weight management. https://www.fda.gov/media/71252/download
- FDA. 2017. Small entity compliance guide on structure/function claims. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-structurefunction-claims
- FDA. 2018. Guidance for industry: Substantiation for dietary supplement claims made under section 403(r) (6) of the federal food, drug, and cosmetic act. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-substantiation-dietary-supplement-claims-made-under-section-403r-6-federal-food
- FDA. 2022a. Structure/Function Claims. https://www.fda.gov/food/food-labeling-nutrition/structurefunction-claims?msclkid=e4fd12b6a61c11ec80961d2a07f7232d.
- FDA. 2022b. Food labeling: Nutrient content claims; Definition of term ‘“healthy”’. https://www.regulations.gov/document/FDA-2016-D-2335-1152.
- FDA. 2022c. Weight-Loss and Weight-Management Devices. https://www.fda.gov/medical-devices/products-and-medical-procedures/weight-loss-and-weight-management-devices#:∼:text=Overweight%20and%20Obesity,-Overweight%20and%20obesity&text=A%20BMI%20of%2030%20kg,that%20are%20associated%20with%20obesity.
- FDA. 2022d. Investigational new drug applications; exemptions for clinical investigations to evaluate a drug use of a product lawfully marketed as a conventional food, dietary supplement, or cosmetic. FDA; A Proposed Rule by the Food and Drug Administration on 12/09/2022 https://www.federalregister.gov/documents/2022/12/09/2022-26728/investigational-new-drug-applications-exemptions-for-clinical-investigations-to-evaluate-a-drug-use.
- FDA. 2023a. Obesity and overweight. https://www.cdc.gov/nchs/fastats/obesity-overweight.htm.
- FDA. 2023b. CFR - Code of Federal Regulations Title 21. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=312.
- FDA. 2023c. Specific requirements for descriptive claims that are neither nutrient content claims nor health claims. FDA; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?fr=101.93#:∼:text=Disease%20claims.,in%20this%20definition.
- FDA. 2023d. FDA announces additional steps to modernize clinical trials 2023. https://www.fda.gov/news-events/press-announcements/fda-announces-additional-steps-modernize-clinical-trials.
- FDA. Fed Regist. 2000. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule. https://www.federalregister.gov/documents/2000/01/06/00-53/regulations-on-statements-made-for-dietary-supplements-concerning-the-effect-of-the-product-on-the
- FMCG. 2023. Consumer perceptions on health and wellness. https://fmcggurus.com/blog/fmcg-gurus-consumer-perceptions-on-health-and-wellness/#:∼:text=Health%20benefits/claims%2C%20price%20and,term%20health%20and%20mental%20wellbeing.
- FTC. 1994. Enforcement policy statement on food advertising. https://www.ftc.gov/legal-library/browse/enforcement-policy-statement-food-advertising.
- FTC. 1997. Abbott settles FTC charges of deceptive claims for its “ensure” nutritional products. https://www.ftc.gov/news-events/news/press-releases/1997/01/abbott-settles-ftc-charges-deceptive-claims-its-ensure-nutritional-products.
- FTC. 2016. POM Wonderful LLC, et al. https://www.ftc.gov/legal-library/browse/cases-proceedings/pom-wonderful-llc-et-al.
- FTC. 2021. Nordic clinical, Inc. and Encore Plus Solutions, Inc. https://www.ftc.gov/legal-library/browse/cases-proceedings/172-3132-172-3143-nordic-clinical-inc-encore-plus-solutions-inc
- FTC. 2022a. Health products compliance guidance. https://www.ftc.gov/system/files/ftc_gov/pdf/Health-Products-Compliance-Guidance.
- FTC. 2022b. FTC proposed order stops marketers from continuing to promote supplements using baseless health claims. [cited 2023 Apr 5]. https://www.ftc.gov/news-events/news/press-releases/2022/03/ftc-proposed-order-stops-marketers-continuing-promote-supplements-using-baseless-health-claims.
- FTC. 2022c. Health and fitness claims. https://www.ftc.gov/news-events/topics/truth-advertising/health-claims
- Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. 2015. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 13(1):74. doi: 10.1186/s12916-015-0322-7.
- Hales CM, Servais J, Martin CB, Kohen D. 2019. Prescription drug use among adults aged 40-79 in the United States and Canada. NCHS Data Brief. No. 347 August 2019. https://www.cdc.gov/nchs/products/index.htm.
- He Z, Rizvi RF, Yang F, Adam TJ, Zhang R. 2019. Comparing the study populations in dietary supplement and drug clinical trials for metabolic syndrome and related disorders. AMIA Jt Summits Transl Sci. 2019:799–808.
- Heaney RP. 2014. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev. 72(1):48–54. doi: 10.1111/nure.12090.
- Herndon MB, Schwartz LM, Woloshin S, Welch HG. 2007. Implications of expanding disease definitions: the case of osteoporosis. Health Aff (Millwood). 26(6):1702–1711. doi: 10.1377/hlthaff.26.6.1702.
- Hsu M, Harper C, Gibson A, Sweeting A, McBride J, Markovic T, Caterson I, Byrne N, Sainsbury A, Seimon R, 2018. Recruitment strategies for a randomised controlled trial comparing fast versus slow weight loss in postmenopausal women with obesity-the TEMPO diet trial. Healthcare Basel Switz. 6(3):76. doi: 10.3390/healthcare6030076.
- Isolauri E, Rautava S, Collado MC, Salminen S. 2015. Role of probiotics in reducing the risk of gestational diabetes. Diabetes Obes Metab. 17(8):713–719. doi: 10.1111/dom.12475.
- Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SAA, Black HR, Blanchette P,Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O’Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D. 2006. Calcium plus Vitamin D supplementation and the risk of fractures. N Engl J Med. 354(7):669–683. doi: 10.1056/NEJMoa055218.
- Jones ML, Martoni CJ, Prakash S. 2012. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 66(11):1234–1241. doi: 10.1038/ejcn.2012.126.
- Lamprea-Montealegre JA, Zelnick LR, Hall YN, Bansal N, de Boer IH. 2018. Prevalence of hypertension and cardiovascular risk according to blood pressure thresholds used for diagnosis. Hypertension. 72(3):602–609. doi: 10.1161/HYPERTENSIONAHA.118.11609.
- Lappe JM, Heaney RP. 2012. Why randomized controlled trials of calcium and vitamin D sometimes fail. Dermatoendocrinol. 4(2):95–100. doi: 10.4161/derm.19833.
- Lebel V, Alderson M, Aita M. 2014. Physiological stability: a concept analysis. J Adv Nurs. 70(9):1995–2004. doi: 10.1111/jan.12391.
- Long J. 2023. CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claims. Natural Products Insider. https://www.naturalproductsinsider.com/supplement-regulations/crn-petition-to-ftc-rcts-aren-t-required-to-substantiate-health-benefit-claims
- Mahmood SS, Levy D, Vasan RS, Wang TJ. 2014. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 383(9921):999–1008. doi: 10.1016/S0140-6736(13)61752-3.
- Margolis CZ. 1983. Uses of clinical algorithms. JAMA. 249(5):627–632. doi: 10.1001/jama.1983.03330290049028.
- Martín-Peláez S, Fito M, Castaner O. 2020. Mediterranean diet effects on type 2 diabetes prevention, disease progression, and related mechanisms. A review. Nutrients. 12(8):2236. https://www.mdpi.com/2072-6643/12/8/2236. doi: 10.3390/nu12082236.
- Masterson D. 2023. Mood is the name and multifunctionality is the game. Nutraingredients. Jul 17; https://www.nutraingredients-usa.com/Article/2023/06/29/Mood-is-the-name-and-multifunctionality-is-the-game#.
- Moynihan R, Brodersen J, Heath I, Johansson M, Kuehlein T, Minué-Lorenzo S, Petursson H, Pizzanelli M, Reventlow S, Sigurdsson J,Stavdal, A Treadwell, J and Glasziou P. 2019. Reforming disease definitions: a new primary care led, people-centred approach. BMJ Evid Based Med. 24(5):170–173. https://ebm.bmj.com/content/ebmed/24/5/170. doi: 10.1136/bmjebm-2018-111148.
- Moynihan R, Cooke GP, Doust JA, Bero L, Hill S, Glasziou PP. 2013. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 10(8):e1001500. doi: 10.1371/journal.pmed.1001500.
- National Academies of Sciences, Engineering, and Medicine. 2022. Defining populations for dietary reference intake recommendations: A letter report. Washington, DC: The National Academies Press; p. 50. https://nap.nationalacademies.org/catalog/26733/defining-populations-for-dietary-reference-intake-recommendations-a-letter-report.
- Nowinski CJ, Bureau SC, Buckland ME, Curtis MA, Daneshvar DH, Faull RLM, Grinberg LT, Hill-Yardin EL, Murray HC, Pearce AJ,Suter CM, White AJ, Finkel AM, Cantu RC. 2022. Applying the Bradford Hill criteria for causation to repetitive head impacts and chronic traumatic encephalopathy. Front Neurol. 13:938163. doi: 10.3389/fneur.2022.938163.
- Parikh CR, Thiessen-Philbrook H. 2014. Key concepts and limitations of statistical methods for evaluating biomarkers of kidney disease. J Am Soc Nephrol. 25(8):1621–1629. https://journals.lww.com/00001751-201408000-00007. doi: 10.1681/ASN.2013121300.
- Perros F, Koumpos A. 2022. Overdiagnosis: The silent pandemic of the West? Public Health Toxicol. 2(1):1–4. http://www.publichealthtoxicology.com/Overdiagnosis-The-silent-pandemic-of-the-West-,145733,0,2.html. doi: 10.18332/pht/145733.
- Raghupathi W, Raghupathi V. 2018. An empirical study of chronic diseases in the United States: A visual analytics approach. Int J Environ Res Public Health. 15(3):431. doi: 10.3390/ijerph15030431.
- Schwartz LM, Woloshin S. 1999. Changing disease definitions: implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey, 1988-1994. Eff Clin Pract. 2(2):76–85.
- SPRINT. 2015. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 373(22):2103–2116. 10.1056/NEJMoa1511939.
- Watanabe K, Wilmanski T, Diener C, Earls JC, Zimmer A, Lincoln B, Hadlock JJ, Lovejoy JC, Gibbons SM, Magis AT,Hood L, Price ND, Rappaport N. 2023. Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention. Nat Med. 29(4):996–1008. https://www.nature.com/articles/s41591-023-02248-0. doi: 10.1038/s41591-023-02248-0.
- Welch G. 2015. Less medicine, more health: 7 assumptions that drive too much medical care. Beacon Press. https://www.beacon.org/Less-Medicine-More-Health-P1095.aspx
- WHO. 2022. WHO definition of health, 1946. WHO. https://www.who.int/about/governance/constitution.
- Worrall J. 2007. Why there’s no cause to randomize. Br J Philos Sci. 58(3):451–488. doi: 10.1093/bjps/axm024.
- Zembic A, Eckel N, Stefan N, Baudry J, Schulze MB. 2021. An empirically derived definition of metabolically healthy obesity based on risk of cardiovascular and total mortality. JAMA Netw Open. 4(5):e218505. doi: 10.1001/jamanetworkopen.2021.8505.
- Ziaeian B, Dinkler J, Guo Y, Watson K. 2016. The 2013 ACC/AHA cholesterol treatment guidelines: Applicability to patients with diabetes. Curr Diab Rep. 16(2):13. doi: 10.1007/s11892-015-0703-5.